Tazarotene

US prescribing information (TAZORAC Cream, Almirall LLC, label date 2025-11-13) — no UK SPC was retrieved, so verify against UK labelling before publishing. PSORIASIS (§2.2): treatment should start with tazarotene cream 0.05%, with the strength increased to 0.1% if tolerated and medically indicated; apply once per day in the evening to cover only the psoriatic lesions. If a bath or shower is taken beforehand the skin should be dry before applying; if emollients are used they should be applied at least an hour before the cream. Unaffected skin may be more susceptible to irritation, so application to those areas should be carefully avoided. ACNE (§2.3): cleanse the face gently and, once the skin is dry, apply a thin layer (2 mg/cm²) of the 0.1% cream once per day in the evening to the areas where acne lesions appear, using enough to cover the entire affected area; use effective sunscreens and wear protective clothing. For topical use only — not for ophthalmic, oral or intravaginal use; if contact with eyes or mucous membranes occurs, rinse thoroughly with water. Wash hands thoroughly after application. Should not be used on eczematous skin (may cause severe irritation); if excessive pruritus, burning, redness or peeling occurs, discontinue until skin integrity is restored, reduce the dosing interval, or in psoriasis switch to the lower concentration. Strengths: 0.05% cream = 0.5 mg tazarotene per gram; 0.1% cream = 1 mg per gram. PAEDIATRIC: safety and efficacy not established under 18 years in psoriasis, or under 12 years in acne.